Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 14/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770571 | 0.89 | KMT2A (0.46) | FFAR1MAOBMAOAMEN1HTT | |
| SCHEMBL14770568 | 0.89 | MEN1 (0.47) | MAOBMEN1HTTKMT2AKDM4E | |
| SCHEMBL12066056 | 0.89 | FFAR1 (0.49) | FFAR1MAOBMAOAMEN1HTT | |
| SCHEMBL14770508 | 0.85 | KMT2A (0.49) | MEN1HTTKMT2AKDM4EALDH1A1 | |
| SCHEMBL14770598 | 0.84 | KMT2A (0.43) | FFAR1MAOBMEN1HTTKMT2A | |
| SCHEMBL14770595 | 0.84 | MAOA (0.44) | MAOAMEN1HTTKMT2AALDH1A1 | |
| SCHEMBL14770526 | 0.84 | CACNA1C (0.48) | MAOBMEN1HTTKMT2AKDM4E | |
| SCHEMBL14770573 | 0.84 | MEN1 (0.46) | FFAR1MAOBMAOAMEN1HTT | |
| SCHEMBL14770583 | 0.83 | MEN1 (0.44) | MAOBMEN1HTTKMT2AKDM4E | |
| SCHEMBL14770587 | 0.83 | MEN1 (0.46) | FFAR1MAOBMAOAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | FFAR1 1112/4885MAOB 2158/4885MAOA 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.